Search Results

You are looking at 41 - 50 of 69 items for :

  • "bisphosphonates" x
Clear All
Full access

Stephen B. Edge

institution, and the use of bisphosphonates among patients with metastatic breast cancer. However, most of the centers determined that much of the care that was not concordant with the guidelines recommendation was due to physician judgment or patient choice

Full access

Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff and Hannah M. Linden

lack of an accessible nonbone site of metastasis and patient refusal. She was treated with tamoxifen and bisphosphonate therapy with symptomatic improvement, with decline in tumor extent as measured by MRI and FDG-PET ( Figure 1, C ). Because of

Full access

health in patients, including surgical options and bisphosphonates. She provided an overview of clinical trial data showing the equivalence of pamidronate versus zoledronic acid, discussed data showing the survival advantage with zoledronic acid compared

Full access

James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski and Patrick C. Walsh

the FRAX® algorithm. Limited evidence exists about fracture prevention during ADT. Several small, randomized, controlled trials have shown that bisphosphonates increase bone mineral density, a surrogate for fracture risk, during ADT. Intravenous

Full access

Jason Gotlib, Aaron T. Gerds, Prithviraj Bose, Mariana C. Castells, Michael W. Deininger, Ivana Gojo, Krishna Gundabolu, Gabriela Hobbs, Catriona Jamieson, Brandon McMahon, Sanjay R. Mohan, Vivian Oehler, Stephen Oh, Eric Padron, Philip Pancari, Nikolaos Papadantonakis, Animesh Pardanani, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Lindsay Rein, David S. Snyder, Brady L. Stein, Moshe Talpaz, Swapna Thota, Martha Wadleigh, Katherine Walsh, Mary Anne Bergman and Hema Sundar

. Management of Osteoporosis: The use of bisphosphonates (with continued use of antihistamines) is recommended to resolve bone pain and improve vertebral bone mineral density (BMD). 111 Pamidronate and zoledronic acid have demonstrated efficacy, resulting in

Full access

Philip J. Saylor and Matthew R. Smith

similar claims-based analysis also found a significant association between GnRH agonist treatment and clinical fractures (relative risk [RR], 1.21; P < .001). 65 Bisphosphonates, including pamidronate, 66 , 67 zoledronic acid, 68 , 69

Full access

Emma Gargus, Rebecca Deans, Antoinette Anazodo and Teresa K. Woodruff

formation markers, although the sample size was low. 68 Currently, there are no trials on the uses of non-hormonal pharmacotherapies for women with POI, such as bisphosphonates, selective estrogen receptor modulators, or strontium/denosumab. Bisphosphonates

Full access

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead and Maria Ho

(such as docetaxel) outside of a clinical trial is not recommended because of the potential for additive myelosuppression. 26 There are no restrictions on combining radium-223 with denosumab or a bisphosphonate. Given the wide variety of second

Full access

Robert A. Swarm, Amy Pickar Abernethy, Doralina L. Anghelescu, Costantino Benedetti, Sorin Buga, Charles Cleeland, Oscar A. deLeon-Casasola, June G. Eilers, Betty Ferrell, Mark Green, Nora A. Janjan, Mihir M. Kamdar, Michael H. Levy, Maureen Lynch, Rachel M. McDowell, Natalie Moryl, Suzanne A. Nesbit, Judith A. Paice, Michael W. Rabow, Karen L. Syrjala, Susan G. Urba, Sharon M. Weinstein, Mary Dwyer and Rashmi Kumar

radiation to bone, and spinal cord compression, and, in some situations, includes hypercalcemia of malignancy. Although bone-modifying agents (bisphosphonates and denosumab) are primarily used to reduce overall SREs, clinical trials have established that

Full access

Emil Lou, Donna D'Souza and Andrew C. Nelson

partial response to treatment, with decreased size of pulmonary metastases and decreased size of multiple hepatic metastases (overall 30% decrease per RECIST criteria). She also received a bisphosphonate (zolendronic acid) due to her bone metastasis